On November 12, 2003, the Institute of Medicine, a government-supported nonprofit organization, issued a news release announcing the publication of a book entitled *Testosterone and Aging*. The news release stated that after careful evaluation of the pros and cons of conducting a large-scale clinical study of testosterone therapy to treat age-related conditions in men, an expert committee recommended going forward with smaller-scale trials. Concerns about safety and efficacy were clearly spelled out, as in the following excerpt from the Institute of Medicine news release:

“The committee found no compelling evidence of major adverse side effects resulting from testosterone therapy, but the evidence is inadequate to document safety.”

In response to this news release, the news media attacked the use of testosterone therapy as being dangerous and useless. The following excerpt is from an Associated Press story that was widely circulated throughout the US:

“Tens of thousands of aging men are trying testosterone shots, patches, and gel in hopes of regaining youthful vigor and virility. A new book uncovers little evidence it works— or that the therapy is even safe—but recommends careful study to find out.”

In addition, newspapers and other media organizations around the country ran the following headlines on November 12-13 that blatantly distorted the Institute of Medicine book:

“Hormone Safety Doubted—Testosterone Therapy Found 'Inappropriate' for Most Men” ----The Washington Post

“Testosterone Use Grows Despite Risks”--The Boston Globe

“Testosterone: Benefits, Risks Unknown”-- WebMD.com

“Testosterone Not Helpful for Most Men”-- Good Housekeeping
The media has misinterpreted findings about the risks and benefits of testosterone therapy. In this article, Life Extension reviews and critiques the new Testosterone and Aging book and the media's inaccurate portrayal of what the book says.

We found that a major flaw with these kinds of government-sponsored publications is that they are written by “committees of experts” that appear to lack a comprehensive understanding and the clinical experience of using testosterone to treat age-related disorders. For instance, the committee cites studies where testosterone did not produce long-term benefits. Anti-aging doctors, on the other hand, have long known that most men taking testosterone also need aromatase inhibitors to block the conversion of testosterone to estrogen. Too much estrogen in a man nullifies the beneficial effects of testosterone. Excess estrogen also contributes to a number of serious disorders ranging from heart disease to prostate cancer.

These committees also fail to realize the critical importance of individualizing a testosterone replacement program. Life Extension's testosterone protocol, for example, mandates blood testing to ascertain how much testosterone, aromatase inhibitor, and/or 5-alpha reductase blocker are needed based on a person's individual health profile and needs. The studies reviewed and proposed by the Institute of Medicine give groups of aged men the same amounts of testosterone without factoring in critical individual requirements.

In reviewing safety data, the Institute of Medicine's committees bring up every side effect that could possibly occur, but overlook the blood-testing protocols used by most anti-aging physicians to guard against these problems. Despite its concern about possible side effects, the Institute of Medicine recommends initiating clinical trials based on “preliminary evidence” that testosterone therapy may “improve strength, sexual function, cognitive function, and general well being” in aging men. Left out of the news release is evidence that testosterone therapy also reports against osteoporosis, anemia, and heart disease.

The Institution of Medicine's proposed initial clinical trials would ascertain the efficacy of testosterone therapy over a one-to-two year period. Once efficacy is established, much longer trials would be needed to ascertain safety.

While the Life Extension Foundation endorses more human clinical trials, the concern is that the study design may be so badly flawed that the results will not reflect the benefits attainable if proper male hormone modulation therapy is administered. Proper testosterone therapy involves the use of drugs to block excess estrogen and DHT (dihydrotestosterone), in addition to individualizing the dose of testosterone. As this will be a government-funded study, the needs of the “individual” are seldom factored in.

It is becoming increasingly clear that government studies are designed for the masses, not for the individual who wants to follow a scientifically designed program to forestall the degenerative effects of aging. In this article, you will see why the government is not the appropriate body to determine the risk-benefit ratio of novel anti-aging therapies, including testosterone replacement.
Estrogen—which is not just one hormone but several related compounds with very similar biological activity—only recently was discovered to be important in many physiological functions in men, including maintenance of bone mass and cognitive function.2 While some estrogen is essential to men's health, too much of it can be quite harmful, especially when in the form of 16-alpha-hydroxyestrone. This chemical, a breakdown product of estrogen metabolism, has high estrogenic activity and has been implicated for its carcinogenic activity. Another estrogen metabolite, 2-hydroxyestrone, is believed to be much less harmful, and a ratio tilting toward the 2-hydroxyestrone is thought to be beneficial.

Testosterone Decline: Andropause

From the beginning of human record, priests, saints, medicine men, farmers and sluits have been demonstrating how clear-cut, sure, and simple it was to take the vigor of animals and men away. How? By removing their testicles.3
—Paul de Kruif, The Male Hormone

Total testosterone levels peak in a man at approximately age 30; by age 40, 5% of men are thought to have low testosterone levels, and by age 70, that figure goes up to at least 40-50%.4 In addition to the absolute change in total testosterone levels, changes also are seen in the ratio of free testosterone to testosterone bound to SHBG. In many aging men, and certainly in those who are obese, free testosterone levels drop significantly as SHBG levels increase and “bind up” the remaining free testosterone.

Testosterone is vitally important for both its anabolic properties including effects on maintaining healthy cholesterol levels, protein synthesis, muscle mass, and bone density, and its androgenic effects including the development and maintenance of male secondary sex characteristics (deep voice, increase in facial and body hair, muscle development) and sexual functions such as libido and erectile capability.

As men age and testosterone levels decrease, classic signs of testosterone deficiency—andropause—frequently appear. These signs include thinning hair, decreasing libido, increasing fat mass and declining muscle mass, and even depression. It is no wonder that in the Institute of Medicine’s Testosterone and Aging,5 the authors state: “more than 1.75 million prescriptions for testosterone products were written in 2002, an estimated increase of 30 percent over the approximately 1.35 million prescriptions in 2001, and an increase of 170 percent from the 648,000 prescriptions in 1999.”

Institute of Medicine Report: A Fair Examination?

Because of both the large increase in testosterone use among men and the aging of the estimated 50-70 million members of the baby-boom generation, in 2002 the National Institute on Aging and the National Cancer Institute directed the Institute of Medicine to assess the benefits and risks of testosterone supplementation among older men. The result was a 217-page book released in November 2003. The group of physicians and scientists that authored the book reviewed a significant portion of already published material on testosterone replacement therapy, and offered its own conclusions on whether and how to conduct future studies of testosterone supplementation.

The Institute of Medicine book begins with an introduction that reviews testosterone synthesis and its action on the human body, as well as a short section on testosterone replacement therapy. This introductory section is generally factual and devoid of any overt bias, but also contains some incorrect statements. On p. 23, the authors state:

“Although some older men who have tried testosterone therapy report feeling ‘more energetic’ or ‘younger,’ testosterone supplementation remains a scientifically unproven method for preventing or relieving any physical or psychological change that men may experience as they get older.”

The following 92 pages of the book, however, detail study after study showing the efficacy of testosterone supplementation therapy in alleviating the multiple symptoms of andropause. Because of this and similar inconsistencies throughout the book, the Institute of Medicine’s findings almost certainly will be suspect in the eyes of many anti-aging researchers. This is one of the problems inherent in the authoring of books by “committees of experts.”

Testosterone Alleviates Andropause Disorders

The next section of the book, “Testosterone and Health Outcomes,” cites various studies showing that testosterone supplementation can play a significant role in alleviating many symptoms of andropause, including the loss of bone and muscle mass, depression, loss of sexual functioning, and heart disease.

This section begins by acknowledging that multiple studies have conclusively proven that testosterone levels significantly decline at a steady rate of 1-2% each year in aging men. Some of the studies
cited, such as the Massachusetts Male Aging Study that examined testosterone levels in 1,709 men aged 39 to 70, showed that good health among aging men correlates with higher levels of testosterone.

Following this admission, the authors then spend the next 72 pages on an extensive review of the literature detailing how testosterone supplementation can affect many common symptoms of andropause. In the section on testosterone levels and bone mass, the authors state on p. 45:

"Several studies with large sample sizes that controlled for age and other potential confounding factors found that lower levels of bioavailable testosterone were associated with lower bone density..." and "low levels of testosterone have been identified as a risk factor for hip fractures."

This section continues by citing literature detailing testosterone's effect on muscle mass, body composition, and physical function. The Institute of Medicine authors correctly state that the loss of muscle mass (sarcopenia) is a significant cause of disability in the elderly, thus making the study of supplements such as testosterone all the more important. Although multiple studies show that testosterone supplementation does help aging men regain muscle mass, the Institute of Medicine hedges on this issue, stating on p. 51 that "research findings regarding testosterone and various body composition measures have been inconsistent, although many studies find an increase in total or abdominal fat mass with decreased testosterone levels."

One such study, which, surprisingly, is not cited by the Institute of Medicine, shows conclusively that testosterone levels are vitally important for overall physical function in aging men. Published in the Journal of Endocrinology and Metabolism, this study of 40 healthy men, aged 73 to 94 years, examined decreases in muscle strength, bone mass, and body composition seen in aging males and their relationship to falling testosterone levels. The researchers measured the men's hormonal levels and ran multiple tests to gauge their body composition, muscle strength, and bone mass. Their findings were not surprising, at least to physicians well versed in anti-aging medicine—muscle strength and bone mass were at optimal levels in men with the highest levels of free testosterone. According to the authors of this independent study, "a number of clinical problems present in older men may be related to androgen [testosterone] deficiency, including reduced muscle mass, changes in body composition, and loss of BMD [bone mass density]."

**Low Testosterone Tied to Health Disorders**

While optimal testosterone levels are needed to maintain muscle mass and bone strength, testosterone also is needed for cognition, sexual functioning, and even heart health. Multiple studies have confirmed that men who maintain optimal testosterone levels as they age have significantly fewer symptoms of mental senility when compared to men with low levels of testosterone.

The Institute of Medicine book confirms this and cites three widely publicized, randomized, placebo-controlled studies showing that testosterone supplementation improves verbal memory, working memory, and visuospatial performance in elderly men. Unfortunately, the Institute of Medicine omits a landmark study published in 2002 in which 407 men, aged 50 to 91, were followed for 10 years and had multiple tests to determine their testosterone levels and cognitive functioning. The authors of this independent study concluded:

"Higher FTI [free testosterone levels] was associated with better scores on visual and verbal memory, visuospatial functioning, and visuomotor scanning and a reduced rate of longitudinal decline in visual memory."

An even more recent study also overlooked by the Institute of Medicine shows that elderly men who suffered from Alzheimer's disease had lower-than-expected levels of testosterone, which the authors hypothesize may be due to brain degeneration seen in Alzheimer's sufferers. The study authors are now investigating whether low testosterone levels precede cognitive dysfunction in men at risk for Alzheimer's. If they do, then testosterone replacement therapy could be warranted for men with lower-than-normal testosterone levels to potentially ward off Alzheimers' disease.

Testosterone supplementation has been shown in multiple studies to improve libido and erectile capability when administered to aging men. Given basic scientific knowledge of how testosterone plays a key role in men's sexual development during puberty and functioning during adulthood, results such as this should come as no surprise. The Institute of Medicine, however, only grudgingly acknowledges the role that testosterone supplementation can play in improving sexual performance in men, stating on p. 70 that "overall, there is some suggestion that testosterone therapy may be beneficial [in terms of sexual functioning] to men with low baseline testosterone levels."

The Institute of Medicine book includes a brief, three-page section (pp. 77-80) on the possible effects of testosterone and heart health in
Aging men. With cardiovascular disease being the numberone killer of men in the US and most Western industrialized nations, it is surprising that the Institute of Medicine does not give this very important topic more consideration. As in other sections of the book, the authors overlook studies showing the beneficial effects of testosterone on heart disease, such as the Rotterdam Study, in which researchers examined testosterone levels and cardiac health among 504 men aged 67 to 75. The researchers conclusively showed that men with higher levels of testosterone had lower levels of coronary artery disease.15 The Rotterdam researchers concluded:

“We found an independent inverse association between levels of endogenous testosterone and severe aortic atherosclerosis and progression of aortic atherosclerosis in men.”

It is a mystery why the Institute of Medicine would exclude such a well-designed study and state on p. 77 that “heart and vascular diseases have a complex multifactorial etiology, and the role of testosterone in this mix has yet to be determined.”

Does Testosterone Cause Prostate Cancer?

Mainstream medical practitioners often have stated that prostate cancer, which in 2003 was responsible for the deaths of more than 29,000 men in the US, is caused by testosterone. Fortunately, the Institute of Medicine includes some data showing that optimal levels of testosterone do not cause prostate cancer, and in fact may protect against this major killer of elderly men. On p. 90, the authors state:

“Population-based studies clearly document the relationship between aging and both increase in prostate cancer incidence rates and decreases in circulating [and free] testosterone levels. While this relationship does not equal causality, the findings do raise intriguing hypotheses regarding the influence of testosterone on inhibiting prostate carcinogenesis.”

Estrogen's Role in Prostate Cancer

Unfortunately, while the Institute of Medicine spends 11 pages (pp. 87-98) detailing testosterone's effect on the prostate, it offers no discussion of the possible effects of estrogen on prostate and its role in prostate cancer. The belief that estrogen, rather than testosterone, is one of the prime normal regulators of prostate cancer is based on the fact that while testosterone levels are highest in young men, prostate cancer essentially is never seen in this population. It is only in older men, who have lower levels of testosterone but higher levels of estrogen and its breakdown products, that prostate cancer is a significant health threat. Animal studies have shown that male rats treated with testosterone alone showed significantly less prostate growth compared to animals treated with both testosterone and estrogen.16 A 1993 study showed that men treated with DHT (which cannot convert to estrogen) saw a reduction in the size of their prostate with no sign of prostate cancer.17 An article published in 2003 in the World Journal of Urology sums up the estrogen-prostate cancer link succinctly: “Estrogenic stimulation through estrogen receptor alpha in a milieu of decreasing androgens [testosterone] contributes significantly to the genesis of benign prostates hyperplasia, prostate dysplasia, and prostate cancer.”

The Institute of Medicine's Recommendations

With all the positive studies cited by the Institute of Medicine, it would be reasonable to expect the authors to conclude that testosterone supplementation, to even the most conservative-minded researcher, has been shown to be efficacious for a variety of andropause-related symptoms. Unfortunately, that is not the case. In fact, the authors do not even acknowledge that low testosterone contributes to andropause in any way, shape, or form, as seen in the following quote on p. 100:

“Endogenous testosterone levels clearly decline with aging, but it is not clear if lower levels of serum testosterone affect health outcomes in older men.”

Following this remarkable statement, the authors then conclude on p. 100:

“A systematic review of the medical literature on testosterone therapy, particularly placebo-controlled trials in older men, demonstrated that there is not clear evidence for any of the health outcomes examined.”

Given the mind-set exemplified by the previous statement, the Institute of Medicine's recommendations and conclusions should come as no surprise. On pp. 117-167, the authors detail the committee's key conclusions, considerations, and recommendations, based on their rather skeptical view of testosterone's effect on the aging process in men and the use of testosterone supplementation.

Their first recommendation is to conduct trials of testosterone supplementation only in older men—those aged 65 and above—and to focus on testosterone supplemen
tation as a therapeutic intervention rather than a preventive measure. The problem here is that it is well established—and even acknowledged by the Institute of Medicine—that in most men, testosterone levels begin falling while they are in their forties. While it is certainly worthwhile to try to treat debilitating symptoms of any disease or pathological process, be it an infection or aging, it is almost always better to try to prevent symptoms rather than treat them once they are in place.

The recommendations continue with the idea of starting research trials with studies to determine whether there is any benefit to testosterone supplementation, and if so, then conducting longer-term trials. The glaring problem with these recommendations is that a significant number of clinical trials already have been conducted—many referenced by the Institute of Medicine—that prove the efficacy of testosterone supplementation for treating a variety of andropause-related symptoms. In addition, longer-term studies of up to three years already have been conducted and have established the usefulness of testosterone supplementation in both middle-aged and elderly men. In the journal *The Aging Male*, researchers recently presented the findings of a three-year study of 122 men, aged 19 to 67, who were treated with testosterone gel. As with numerous earlier studies, the study authors found that long-term treatment with testosterone supplementation causes a statistically significant improvement in bone mineral mass and sexual desire, an increase in muscle mass, and a decrease in fat mass.

The Institute of Medicine's final recommendation concerns the safety of the men participating in the testosterone supplementation trial. To accomplish this, the committee would set up stric exclusion criteria, mandate careful monitoring of markers of prostate function such as PSA (prostate specific antigen) levels, and seek to ascertain whether long-term testosterone supplementation can cause a rise in prostate cancer.

**Conclusions of the Institute of Medicine**

In the Institute of Medicine book's final pages (pp. 163-7) preceding the appendixes, the authors cast a derisive eye on the myriad reports showing the effectiveness of testosterone supplementation, concluding:

"The trials that have been conducted do not show definitively that there are benefits of testosterone therapy for older men...the committee recommends short-term efficacy trials to determine if there are benefits of testosterone therapy in older men."

Apparently, at the cost of the health and possibly lives of many thousands of middle-aged and elderly men, the Institute of Medicine committee has decided that yet another trial of testosterone supplements should be conducted, a trial that will take years and be funded by taxpayers, while those very same taxpayers are suffering from the very real, and often very debilitating symptoms, of andropause-induced testosterone deficiency.

Instead of reading the Institute of Medicine's book, the media instead chose to malign the multiple benefits of testosterone replacement and exaggerate its potential side effects. *Testosterone and Aging* cites numerous clinical studies showing significant anti-aging effects, but the media reported only the disparaging conclusions made by certain committee members that had little or no basis in fact.

Unlike the mainstream media we actually read the book, which provides solid scientific evidence that aging men should seek to maintain youthful testosterone levels. Turn this page to learn how to safely restore testosterone in aging men.